✦ LIBER ✦

Successful Treatment with Imatinib Mesylate in a Case of Minor BCR-ABL-Positive Acute Myelogenous Leukemia

✍ Scribed by Katsuro Ito; Kazunori Tominaga; Toshiya Suzuki; Itsuro Jinnai; Masami Bessho

Book ID: 119988978
Publisher: Carden Jennings Publishing
Year: 2005
Tongue: English
Weight: 69 KB
Volume: 81
Category: Article
ISSN: 0925-5710
DOI: 10.1532/ijh97.04098

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Increasing the BCR-ABL expression levels

Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia

✍ S. Grammatico; L. Elia; A.L. Peluso; L. Pedace; M. Matarazzo; A. Vitale; A. Rago 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 275 KB

Chronic Myelogenous Leukemia with the e6

Chronic Myelogenous Leukemia with the e6a2 BCR-ABL and Lacking Imatinib Response: Presentation of Two Cases

✍ Vefring, Hege K.; Gruber, Franz X.E.; Wee, Line; Hovland, Randi; Hjorth-Hansen, 📂 Article 📅 2009 🏛 S. Karger AG 🌐 English ⚖ 272 KB

Safety and efficacy of STI-571 (imatinib

Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT)

✍ Fischer, T; Reifenrath, C; Hess, G R; Corsetti, M T; Kreil, S; Beck, J; Meinhard 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 253 KB

Insights from pre-clinical studies for n

Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective

✍ La Rosée, P; O’Dwyer, M E; Druker, B J 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 132 KB

Successful treatment of imatinib-resista

Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation

✍ Corm, S; Renneville, A; Rad-Quesnel, E; Grardel, N; Preudhomme, C; Quesnel, B 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 76 KB

Philadelphia chromosome-positive acute m

Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) treated with imatinib mesylate (IM): A report with IM plasma concentration and bcr-abl transcripts

✍ Toshinori Kondo; Taizo Tasaka; Fuminori Sano; Kimiko Matsuda; Yasutaka Kubo; Yos 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 159 KB

We studied the efficacy and pharmacokinetics of imatinib mesylate (IM) and bcr-abl expression in a Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) patient, a rare disease with a poor prognosis. Although sufficient IM trough concentrations were maintained, bcr-abl transcripts revea